Captor Therapeutics S.A. (CTX)
GPW
70.10
+0.30 (+0.43%)
Closed
Sep 25, 2026
Day's Range
69.8070.90
52 wk Range
36.5089.20
Financial Statements - CTX - Captor Therapeutics S.A.
Revenue
4.66M▼ 70.6%
Net Income
-41.99M▼ 9.3%Net Margin -901.2%
EBITDA
-37.42M▼ 13.5%
Free Cash Flow
-37.53M▼ 16.2%
Income Statement
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|---|---|
| Sales | 4.66M | 15.82M | 13.20M | 9.15M | 3.98M | 0 |
| Cost of Goods | 1.44M | 5.23M | 6.30M | 2.08M | 741K | - |
| Gross Profit | 3.21M | 10.59M | 6.90M | 7.07M | 3.24M | 0 |
 Operating Expense | - | - | - | - | - | - |
| Operating Income | -43.63M | -38.96M | -73.01M | -40.36M | -32.70M | -12.21M |
| Non-Operating Interest | - | - | - | - | - | - |
| Other Income Expense | - | - | - | - | - | - |
| Pre Tax Income | -41.99M | -38.42M | -70.52M | -35.89M | -32.57M | -12.69M |
| Income Tax | 0 | 0 | 57K | 0 | 0 | 0 |
| Net Income | -41.99M | -38.42M | -70.58M | -35.89M | -32.57M | -12.69M |
| EPS Basic | -7.61 | -8.25 | -15.19 | -8.61 | -7.89 | -3.908046 |
| EPS Diluted | -7.61 | -8.25 | -15.19 | -8.61 | -789 | -3.908046 |
| Basic Shares Outstanding | 5.51M | 4.65M | 4.64M | 4.16M | 4.12M | 3.24M |
| Diluted Shares Outstanding | 5.51M | 4.65M | 4.64M | 4.16M | 4.12M | 3.24M |
| Ebit | -41.72M | -38.04M | -70.25M | -35.57M | -32.17M | -12.30M |
| Ebitda | -37.42M | -32.98M | -64.81M | -30.47M | -25.81M | -5.69M |
| Net Income Continuous Operations | -41.99M | -38.42M | -70.58M | -35.89M | -32.57M | -12.69M |
| Minority Interests | 0 | 0 | 0 | 0 | 0 | - |
| Preferred Stock Dividends | 0 | 0 | 0 | 0 | 0 | 0 |
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
